Artisan Partners Limited Partnership Sells 15,710 Shares of Immatics (NASDAQ:IMTX)

Artisan Partners Limited Partnership decreased its position in Immatics (NASDAQ:IMTX) by 2.4% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 645,607 shares of the company’s stock after selling 15,710 shares during the period. Artisan Partners Limited Partnership’s holdings in Immatics were worth $4,590,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. Frazier Life Sciences Management L.P. grew its holdings in Immatics by 17.5% in the 3rd quarter. Frazier Life Sciences Management L.P. now owns 1,354,711 shares of the company’s stock worth $15,457,000 after acquiring an additional 202,255 shares during the last quarter. Wellington Management Group LLP grew its stake in shares of Immatics by 1.5% in the third quarter. Wellington Management Group LLP now owns 9,681,183 shares of the company’s stock worth $110,462,000 after purchasing an additional 144,549 shares during the last quarter. abrdn plc increased its holdings in Immatics by 49.2% during the 4th quarter. abrdn plc now owns 347,379 shares of the company’s stock valued at $2,470,000 after purchasing an additional 114,479 shares during the period. Platinum Investment Management Ltd. raised its position in Immatics by 53.1% during the 4th quarter. Platinum Investment Management Ltd. now owns 311,722 shares of the company’s stock valued at $2,216,000 after purchasing an additional 108,108 shares during the last quarter. Finally, Y Intercept Hong Kong Ltd bought a new position in Immatics during the 4th quarter valued at approximately $211,000. 64.41% of the stock is owned by hedge funds and other institutional investors.

Immatics Stock Performance

Shares of IMTX stock opened at $4.63 on Friday. Immatics has a fifty-two week low of $4.06 and a fifty-two week high of $13.77. The firm has a market cap of $552.62 million, a P/E ratio of -7.02 and a beta of 0.83. The business’s 50 day moving average price is $4.96 and its 200-day moving average price is $7.46.

Immatics (NASDAQ:IMTX) last released its quarterly earnings results on Thursday, March 27th. The company reported $0.48 earnings per share for the quarter, beating the consensus estimate of ($0.03) by $0.51. Immatics had a negative net margin of 47.94% and a negative return on equity of 15.90%. The business had revenue of $15.67 million for the quarter, compared to analysts’ expectations of $16.16 million. As a group, equities analysts predict that Immatics will post -0.72 EPS for the current year.

About Immatics

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.